Abstract 377: Molecular features-based model for predicting benefit from Bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor - KIVIRID

Abstract 377: Molecular features-based model for predicting benefit from Bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor

Authors: Yongchang Zhang, Analyn Lizaso

Published: 2021-07-01

DOI: 10.1158/1538-7445.am2021-377

Source: Full article

Abstract

Abstract